STOCK TITAN

AN2 Therapeutics, Inc. - ANTX STOCK NEWS

Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.

AN2 Therapeutics, Inc. (Nasdaq: ANTX) is a clinical-stage biopharmaceutical company based in California focusing on developing innovative treatments for rare, chronic, and serious infectious diseases. The company’s mission is to harness modern biomedical expertise to create transformative medicines for patients globally. AN2’s leading drug candidate, epetraborole, targets non-tuberculous mycobacterial (NTM) lung disease, an often fatal and progressive bacterial infection.

Currently, AN2 is conducting a pivotal Phase 2/3 clinical trial of epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease. The trial, which operates across over 100 clinical sites in the U.S., Japan, South Korea, and Australia, aims to provide a new oral treatment option for patients with limited alternatives. The company recently announced the voluntary pause of Phase 3 enrollment following an analysis of Phase 2 data, allowing time for more in-depth review and potential modifications based on feedback from the FDA.

AN2 Therapeutics reported robust financial health with cash and investments of $118.1 million as of March 31, 2024, ensuring the continuation of their research and development endeavors. Besides epetraborole, AN2 is also progressing in other areas such as Chagas disease and tuberculosis, supported by grants from the Bill & Melinda Gates Foundation and collaborations with esteemed institutions like the University of Georgia.

The company's dedication to addressing unmet medical needs is further demonstrated through its boron chemistry platform, which aims to discover novel therapies for global health challenges. With ongoing clinical trials and a solid financial foundation, AN2 Therapeutics positions itself as a key player in the fight against infectious diseases.

Rhea-AI Summary
AN2 Therapeutics, Inc. (ANTX) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Eric Easom, Co-Founder, President and CEO, will provide a corporate overview on February 14, 2024. The webcast can be accessed on the Investors section of the AN2 Therapeutics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences
-
Rhea-AI Summary
ANTX: AN2 Therapeutics reports enrollment in Phase 3 of pivotal Phase 2/3 epetraborole study for MAC lung disease, presents new data at IDWeek 2023, and secures $150.2 million cash runway through summer 2025
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
-
Rhea-AI Summary
AN2 Therapeutics, Inc. (Nasdaq: ANTX) will participate in two upcoming investor conferences in November. Eric Easom, Co-Founder, President and CEO, will provide a corporate overview at the Stifel 2023 Healthcare Conference on November 15 at 3:00 p.m. ET and at the 6th Annual Evercore ISI HealthCONx Conference on November 29 at 8:45 a.m. ET. The presentations can be accessed on the AN2 Therapeutics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.91%
Tags
conferences
Rhea-AI Summary
AN2 Therapeutics receives exclusive license to advance development of boron-based small molecule for Chagas disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
-
Rhea-AI Summary
AN2 Therapeutics announces enrollment ongoing in Phase 3 trial of Epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
conferences
-
Rhea-AI Summary
AN2 Therapeutics, Inc. has received a research grant from the Bill & Melinda Gates Foundation to develop treatments for tuberculosis and malaria. The funding will support the discovery of novel inhibitors using AN2's boron chemistry platform. This grant underscores AN2's commitment to addressing high unmet needs in global health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.26%
Tags
none
Rhea-AI Summary
AN2 Therapeutics announces Phase 2 enrollment completion and initiation of Phase 3 for epetraborole, with topline results expected in summer 2024. Epetraborole has potential to become backbone therapy for MAC lung disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
-
Rhea-AI Summary
AN2 Therapeutics, Inc. announces pricing of underwritten offering of 7,777,778 shares of common stock at $9.00 per share, expected to raise approximately $70.0 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
conferences

FAQ

What is the current stock price of AN2 Therapeutics (ANTX)?

The current stock price of AN2 Therapeutics (ANTX) is $1.3 as of November 20, 2024.

What is the market cap of AN2 Therapeutics (ANTX)?

The market cap of AN2 Therapeutics (ANTX) is approximately 36.1M.

What does AN2 Therapeutics, Inc. specialize in?

AN2 Therapeutics focuses on developing treatments for rare, chronic, and serious infectious diseases.

What is the main product candidate of AN2 Therapeutics?

The main product candidate is epetraborole, a once-daily oral treatment for non-tuberculous mycobacterial (NTM) lung disease.

What is the current status of epetraborole’s clinical trials?

Epetraborole is undergoing a pivotal Phase 2/3 clinical trial for treatment-refractory Mycobacterium avium complex (MAC) lung disease.

Has AN2 Therapeutics halted any part of their clinical trials?

Yes, AN2 voluntarily paused Phase 3 enrollment of their Phase 2/3 trial due to the need for further data evaluation.

What recent financial updates were provided by AN2 Therapeutics?

AN2 reported cash and investments of $118.1 million as of March 31, 2024, ensuring funding for their operations through mid-2025.

Who are some of the major collaborators and supporters of AN2 Therapeutics' research?

AN2 has received support and collaboration from the Bill & Melinda Gates Foundation and the University of Georgia.

What other diseases is AN2 Therapeutics targeting apart from NTM lung disease?

AN2 is also working on treatments for Chagas disease, tuberculosis, and malaria using their proprietary boron chemistry platform.

When is the Phase 2 topline data for epetraborole expected to be announced?

The topline data from the Phase 2 part of the epetraborole trial is expected to be announced in August 2024.

What is the vision of AN2 Therapeutics?

AN2 Therapeutics aims for a world free from the threat of infectious diseases by developing life-saving new treatments.

Where can I find more information about AN2 Therapeutics?

You can visit their official website at www.an2therapeutics.com for more detailed information.

AN2 Therapeutics, Inc.

Nasdaq:ANTX

ANTX Rankings

ANTX Stock Data

36.08M
23.24M
21.64%
52.31%
0.45%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MENLO PARK